Alnylam 8-K: Officer Compensation, Director Changes Reported
Ticker: ALNY · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: executive-compensation, corporate-governance, personnel-change
TL;DR
**Alnylam filed an 8-K on Jan 19 about officer compensation and potential director changes from Jan 12.**
AI Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 12, 2024. This filing primarily concerns changes in compensatory arrangements for certain officers and potentially the departure or election of directors or officers, as indicated by Item 5.02. While specific details of these changes are not provided in the excerpt, any significant alterations to executive compensation or leadership could impact investor confidence and the company's strategic direction, making it important for shareholders to monitor the full filing for specifics.
Why It Matters
Changes in executive compensation or leadership can signal shifts in company strategy or financial health, directly influencing investor perception and stock valuation.
Risk Assessment
Risk Level: medium — Without specific details on the compensation changes or personnel shifts, the impact on the company's financial health and future performance remains uncertain, posing a moderate risk.
Analyst Insight
A smart investor would seek out the full 8-K filing to understand the specific details of the compensatory arrangements and any personnel changes, as these could significantly impact future company performance and stock valuation.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — the filer of the 8-K
- January 19, 2024 (date) — date of 8-K filing
- January 12, 2024 (date) — date of earliest event reported
- 001-36407 (dollar_amount) — Commission File Number
FAQ
What specific events did Alnylam Pharmaceuticals, Inc. report in this 8-K filing?
Alnylam Pharmaceuticals, Inc. reported events related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers' as per Item 5.02, and 'Financial Statements and Exhibits' as per Item 9.01.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 12, 2024.
What is the filing date of this 8-K?
The filing date of this 8-K is January 19, 2024.
What is Alnylam Pharmaceuticals, Inc.'s Commission File Number?
Alnylam Pharmaceuticals, Inc.'s Commission File Number is 001-36407.
Where is Alnylam Pharmaceuticals, Inc.'s principal executive office located?
Alnylam Pharmaceuticals, Inc.'s principal executive office is located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts, 02142.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-19 16:31:00
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq
Filing Documents
- d701085d8k.htm (8-K) — 24KB
- 0001193125-24-011278.txt ( ) — 142KB
- alny-20240112.xsd (EX-101.SCH) — 3KB
- alny-20240112_lab.xml (EX-101.LAB) — 18KB
- alny-20240112_pre.xml (EX-101.PRE) — 11KB
- d701085d8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On January 12, 2024, Alnylam Pharmaceuticals, Inc. (the "Company") and Indrani L. Franchini agreed that she would transition from her role as the Company's Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024 (the "Separation Date"). In connection with her transition, Ms. Franchini and the Company intend to enter into a written agreement not later than the Separation Date, which will contain the terms of her severance and transition from the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALNYLAM PHARMACEUTICALS, INC. Date: January 19, 2024 By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer